Hodgkin Lymphoma

The implementation of treatment regimens for Hodgkin lymphoma (HL) in the face of COVID-19 is often individualized. Treatments for HL can result in an increased risk of infections and complications due to the immunosuppressive effects of therapy. In addition, standard treatments for HL, including bleomycin and radiation therapy, can increase the risk of pulmonary toxicity....

Written by Nikki Meyer Edited by Lauren Weinand, M.D. This retrospective study, published in Blood, and presented at the 2021 ASH Annual Meeting & Exposition, examined pre-apheresis absolute lymphocyte count (PA-ALC) and post-transplant ALC (PT-ALC) for patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who had received autologous hematopoietic stem cell transplant (auto-HCT). The researchers sought to evaluate the...

Researchers across the United States recently used an oncology simulation model to estimate the survival of patients with classical Hodgkin lymphoma (cHL) for 10 years after treatment. Specifically, the study sought to estimate the future number of patients with stage III or IV cHL who are alive and progression-free over 10 years for patients who...

A new retrospective analysis of pediatric patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL), published in Blood, will be presented at the 2021 ASH Annual Meeting & Exposition. While there is a phase 3 randomized controlled trial supporting the use of brentuximab vedotin (BV) in adults with R/R HL after receiving autologous stem cell transplantation (ASCT),...

A new study, published in Blood, will be presented at the ASH Annual Meeting & Exposition, analyzing the mRNA of adolescent/young adult survivors of Hodgkin lymphoma (AYAHL) and their twins who were unaffected by the disease to further investigate the transcription control pathways involved. The researchers used blood samples from 17 pairs of AYAHL and their twin,...

This study, published in Blood, sought to identify predisposition genes for classic Hodgkin Lymphoma (cHL) in adolescents and young adults using germline whole-exome sequencing (WES). It will be presented at the 2021 ASH Annual Meeting & Exposition.  The researchers gathered index cases of multiplex families to analyze from twin registries and a cancer surveillance program based...

Both angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma of the TFH phenotype exhibit the expression of follicular helper T cell markers. Differential expression and coexpression of these markers in malignant and benign lymphoid proliferations are not well understood. This study, published in the American Journal of Clinical Pathology, examined the expression of these markers...

Hodgkin and Reed-Sternberg cells originate from germinal center B-cells. These cells tend to lose the B-cell phenotype. However, one-third of classic Hodgkin lymphoma cases express at least one B-cell marker, which can lead to difficulties in distinguishing classic Hodgkin lymphoma from B-cell lymphomas. This case report, published in Clinical Lymphoma, Myeloma, and Leukemia, analyzed a case of...

The resistance and progression of tumors in patients with classic Hodgkin lymphoma is believed at least in part to depend on features of the tumor microenvironment. However, the relationship between malignant Hodgkin/Reed-Sternberg cells, reactive populations, and immune cells is still unclear. This retrospective study, published in Cancers, sought to identify potential predictive and prognostic morphological markers in...